Greenyn Biotechnology Co

Greenyn Biotechnology Co Net Margin

The Net Profit Margin of Greenyn Biotechnology Co (6846.TWO) as of Nov 2, 2026 is 15.90 %. In the previous year, Net Profit Margin was 16.72 % — a change of -4.91% (lower).

Net Margin

15.90 %

YoY

-4.91%

Last updated:

Net Profit Margin of Greenyn Biotechnology Co is 2025 15.90 % . Net Profit Margin of Greenyn Biotechnology Co was 2024 16.72 % . It decreases by -4.91% lower compared to the previous year.

Greenyn Biotechnology Co's net margin stands at 15.9%, down from 19.1% several years earlier.

The Greenyn Biotechnology Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
16.20 TWD
Jan 1, 2020
18.65 TWD
Jan 1, 2021
19.14 TWD
Jan 1, 2022
20.80 TWD
Jan 1, 2023
16.32 TWD
Jan 1, 2024
16.72 TWD
Jan 1, 2025
15.90 TWD
The Greenyn Biotechnology Co Net Margin history
YEARNet MarginYoY
15.90 %-4.91%
16.72 %+2.43%
16.32 %-21.54%
20.80 %+8.71%
19.14 %+2.64%
18.65 %+15.08%
16.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Greenyn Biotechnology Co Stock analysis

What does Greenyn Biotechnology Co do? Greenyn Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sales of health food raw materials across three business segments: health ingredients, health formulations, and other segments. Its main products include Antrodia cinnamomea mycelia, Bitter melon extract (Insumate), and 101 Phyto Fermented Drink, which are primarily sold in Taiwan and other Asian regions. The company focuses on supplying these health-focused products to customers within the Asian market, leveraging its product portfolio for regional demand. The firm's product lineup targets health-conscious consumers seeking natural health solutions, with Antrodia cinnamomea mycelia and Bitter melon extract (Insumate) serving as key offerings. 101 Phyto Fermented Drink represents another core product, emphasizing plant-based health benefits. These products are distributed through established channels in Taiwan and neighboring Asian markets, supporting the company's regional sales strategy. Greenyn Biotechnology's business model centers on developing and commercializing specialized health ingredients and formulations, with a strong emphasis on Asian market penetration. The company's revenue streams are derived from the direct sale of its proprietary health food raw materials to customers in Taiwan and other Asian regions, without mentioning external partners or additional distribution channels beyond the specified markets. Greenyn Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Greenyn Biotechnology Co stock

Net Profit Margin of Greenyn Biotechnology Co is 15.90 % in 2025.

Net Profit Margin of Greenyn Biotechnology Co changed from 16.72 % to 15.90 %, representing a -4.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Greenyn Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Greenyn Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Greenyn Biotechnology Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Greenyn Biotechnology Co